Cyclacel Pharmaceuticals Inc.
| NASDAQ: CYCC | Healthcare / Biotechnology / USA |
| 6.39 | -0.1300 | -1.99% | Vol 62.39K | 1Y Perf 1.12% |
| Apr 19th, 2021 11:38 DELAYED |
| BID | 6.33 | ASK | 6.44 | ||
| Open | 6.52 | Previous Close | 6.52 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 21.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 233.28 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 55.97 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 45.39M | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 20.27 | Earnings Date | 11th May 2021 |
Today's Price Range 6.346.70 | 52W Range 3.1219.25 | 5 Year PE Ratio Range -0.5000-1.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -11.89% | ||
| 1 Month | -21.82% | ||
| 3 Months | -11.29% | ||
| 6 Months | 67.61% | ||
| 1 Year | 1.12% | ||
| 3 Years | -77.82% | ||
| 5 Years | -93.78% | ||
| 10 Years | -99.69% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -61.27 | |||
ROE last 12 Months | -54.02 | |||
ROA (5Y Avg) | -43.50 | |||
ROA last 12 Months | -46.46 | |||
ROC (5Y Avg) | -61.75 | |||
ROC last 12 Months | -40.58 | |||
Return on invested Capital Q | -22.18 | |||
Return on invested Capital Y | -52.78 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.80 | ||||
| 2.09 | ||||
| 88.29 | ||||
| - | ||||
| -12.90 | ||||
| -2.18 | ||||
| 2.09 | ||||
| 3.62 | ||||
| 37.07M | ||||
| Forward PE | -3.00 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 14.00 | ||||
| 14.30 | ||||
| 0.03 | ||||
| 0.03 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -6 235.30 | ||||
| -6 220.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.52 | -1.34 | -157.69 |
| Q03 2020 | -0.49 | -0.47 | 4.08 |
| Q02 2020 | -0.47 | -0.58 | -23.40 |
| Q01 2020 | -2.80 | -1.48 | 47.14 |
| Q04 2019 | -2.40 | -2.80 | -16.67 |
| Q03 2019 | -3.40 | -2.20 | 35.29 |
| Q02 2019 | -3.00 | -3.20 | -6.67 |
| Q01 2019 | -3.80 | -3.00 | 21.05 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.50 | -2.04 | Negative |
| 6/2021 QR | -0.52 | -1.96 | Negative |
| 12/2021 FY | -2.23 | -19.25 | Negative |
| 12/2022 FY | -2.46 | 52.60 | Positive |
| Next Report Date | 11th May 2021 |
| Estimated EPS Next Report | -0.50 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 62.39K |
| Shares Outstanding | 7.10M |
| Trades Count | 394 |
| Dollar Volume | 3.68M |
| Avg. Volume | 629.56K |
| Avg. Weekly Volume | 69.54K |
| Avg. Monthly Volume | 127.23K |
| Avg. Quarterly Volume | 679.66K |
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 6.52 per share at the end of the most recent trading day (a -4.4% change compared to the prior day closing price) with a volume of 99.34K shares and market capitalization of 45.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.
The one-year performance of Cyclacel Pharmaceuticals Inc. stock is 1.12%, while year-to-date (YTD) performance is -16.52%. CYCC stock has a five-year performance of -93.78%. Its 52-week range is between 3.12 and 19.25, which gives CYCC stock a 52-week price range ratio of 20.27%
Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 2.09, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.46%, a ROC of -40.58% and a ROE of -54.02%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $21.33, which is +233.28% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cyclacel Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.27, ATR14 : 0.84, CCI20 : -141.39, Chaikin Money Flow : -0.03, MACD : -0.32, Money Flow Index : 31.49, ROC : -2.40, RSI : 41.00, STOCH (14,3) : 7.44, STOCH RSI : 0.44, UO : 39.63, Williams %R : -92.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were:
Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
CEO: Spiro Rombotis
Telephone: +1 908 517-7330
Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US
Number of employees: 12
